Get research updatesSchizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
Investigating the neurobiological and neurocognitive effects of repeated sessions of tDCS and itDCS in schizophrenia.
This study ended early.
In Australia
Investigation of alpha-lipoic acid supplementation on oxidative stress parameters in patients with schizophrenia
This study has finished and is no longer accepting participants.
In Serbia and Montenegro
For individuals with schizophrenia and insomnia, can melatonin and CBT improve sleep, symptoms, functioning and cognitive functions
This study ended early.
In Mount ClaremontMirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial
This study has finished and is no longer accepting participants.
Location not clearly listed
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
This study ended early.
Multiple locations, including FitzroyN-acetyl cysteine in Schizophrenia:A double blind randomised placebo controlled trial investigating a range of psychiatric rating scales
This study has finished and is no longer accepting participants.
Location not clearly listedQuality of Life (QoL) in schizophrenia patients on Abilify Maintena (Aripiprazole) versus treatment with other atypical anti-psychotics (oral or depot) in a private mental health setting: a pilot randomized controlled trial.
This study has finished and is no longer accepting participants.
In AustraliaPrevention or delay of onset of psychosis in an 'ultra high risk' group: A comparison of risperidone and placebo in combination with intensive psychological treatment
This study has finished and is no longer accepting participants.
In AustraliaIn people with treatment resistant schizophrenia, is sodium benzoate a tolerated and acceptable augmentation strategy: a phase Ib/II study.
This study ended early.
In New ZealandThe efficacy of Garcinia mangostana L. (mangosteen) pericarp as an adjunct with second generation antipsychotics for the treatment of Schizophrenia: A double- blind, randomized, placebo controlled trial.
This study has finished and is no longer accepting participants.
In AustraliaThe efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp for the treatment of schizophrenia: A 24-week double blind randomised placebo controlled trial
This study has finished and is no longer accepting participants.
Multiple locations, including HerstonThe impact of oxytocin in Schizophrenia to treat social communication problems.
This study has finished and is no longer accepting participants.
Location not clearly listedWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.